Catatonia Atlas

MDMA

Open this page in the complete interactive Atlas

Read the findings from PTSD and other psychiatric studies alongside the schizophrenia tolerability study and reports of catatonia after ecstasy exposure.

How might it help?

MDMA increases signaling through serotonin, norepinephrine and dopamine. Changes in emotional processing have motivated studies pairing it with psychotherapy for PTSD. The UCLA schizophrenia study asks whether people with stable illness tolerate exposure before drawing conclusions about possible social benefits. NIDA review of MDMA pharmacology Original source UCLA study Original source

24 records

MDMA · Catatonia after recreational ecstasy exposureA 1993 report described low blood sodium and catatonic stupor after ecstasy.
Adverse exposure

Study or clinical setting

Case reports and correspondence

What was reported

A 1993 report described low blood sodium and catatonic stupor after ecstasy. Later authors reported adolescent catatonia after recreational exposure and an adult with chronic MDMA use, psychosis and catatonic signs who improved after electroconvulsive therapy (ECT).

What limits the finding

These reports concern illness after exposure. No human treatment trial of MDMA for catatonia was identified in this search. Tablet composition, other psychiatric illness and medical complications limit causal attribution.

Sources

Open this evidence page

MDMA · Schizophrenia · tolerability and social motivationUCLA plans to study 20 adults with clinically stable schizophrenia.
Safety and mechanism study

Study or clinical setting

Early open-label tolerability study

What was reported

UCLA plans to study 20 adults with clinically stable schizophrenia. Investigators monitor disorganized speech, delusions and hallucinations and explore whether MDMA changes social motivation. This is an early test of whether further study is feasible.

What limits the finding

The registry lists recruiting and has no posted outcomes. There is no demonstrated benefit for schizophrenia symptoms, acute psychosis or catatonia from this trial.

Study identifiers · NCT05770375

Sources

Open this evidence page

MDMA · Psychosis after recreational ecstasy exposureClinicians describe persistent hallucinations, paranoia or disorganization beginning after reported recreational ecstasy use.
Adverse exposure

Study or clinical setting

Individual case reports

What was reported

Clinicians describe persistent hallucinations, paranoia or disorganization beginning after reported recreational ecstasy use. In these reports MDMA exposure preceded symptoms and people subsequently needed psychiatric care.

What limits the finding

Individual histories cannot establish the frequency of this outcome or distinguish drug effects, unverified tablet contents and an underlying psychotic disorder.

Sources

Open this evidence page

MDMA · Post-traumatic stress disorder (PTSD)MAPP1 enrolled 90 adults with severe PTSD.
Treatment study

Study or clinical setting

Two phase 3 randomized, double-blind, placebo-controlled trials

What was reported

MAPP1 enrolled 90 adults with severe PTSD. MAPP2 enrolled 104 with moderate or severe PTSD. In both, the group assigned MDMA plus therapy had larger reductions in clinician-rated PTSD symptoms than the group assigned placebo plus the same therapy. In MAPP2 the estimated mean decrease on the CAPS-5 scale was 23.7 versus 14.8 points.

What limits the finding

Participants could often infer their assignment. The US FDA declined the 2024 application over interpretation and safety data. MAPS acknowledged a reported resubmission in August 2026. No subsequent US approval was identified in the review. Australia has a restricted authorized-psychiatrist access pathway for PTSD. Neither decision establishes efficacy for catatonia or schizophrenia.

Study identifiers · NCT03537014 · NCT04077437

Sources

Open this evidence page

MDMA · PTSD and relationship functioningA pilot integrated MDMA with conjoint therapy in six couples in which one partner had PTSD.
Treatment study

Study or clinical setting

Uncontrolled couple-therapy pilot

What was reported

A pilot integrated MDMA with conjoint therapy in six couples in which one partner had PTSD. A separate 2026 study in eight veterans and their partners also observed improvements in PTSD and relationship scores, with some loss of relationship gains at follow-up.

What limits the finding

Both studies were small and lacked control groups. Changes could reflect conjoint psychotherapy, partner support, expectancy or other factors.

Study identifiers · NCT02876172 · NCT06044675

Sources

Open this evidence page

MDMA · Major depressive disorderTwelve adults with major depressive disorder took part in a feasibility study.
Treatment study

Study or clinical setting

Open-label proof-of-principle study with follow-up

What was reported

Twelve adults with major depressive disorder took part in a feasibility study. Depression scores fell after treatment. A later publication followed the same participants to seven months.

What limits the finding

There was no placebo or psychotherapy-only comparison. The follow-up concerns the original cohort, so independent controlled studies are needed to estimate benefit and durability.

Study identifiers · EudraCT 2021-000805-26

Sources

Open this evidence page

MDMA · Social anxiety in autistic adultsTwelve autistic adults with substantial social anxiety entered the study.
Treatment study

Study or clinical setting

Randomized, blinded, placebo-controlled pilot

What was reported

Twelve autistic adults with substantial social anxiety entered the study. Eight were assigned MDMA-assisted psychotherapy and four received placebo with psychotherapy. Social-anxiety ratings improved more in the active group, with the difference still evident at six months.

What limits the finding

Four people formed the comparison group. The outcome was social anxiety in a selected group of adults, with no conclusions about catatonia or the broader autistic population.

Study identifiers · NCT02008396

Sources

Open this evidence page

MDMA · Social anxiety disorderA trial of 20 adults with social anxiety disorder reported a larger 16-week improvement on the Liebowitz Social Anxiety Scale in participants assigned to immediate MDMA-assisted therapy than in those assigned to wait.
Treatment study

Study or clinical setting

Small randomized, open-label, wait-list-controlled trial

What was reported

A trial of 20 adults with social anxiety disorder reported a larger 16-week improvement on the Liebowitz Social Anxiety Scale in participants assigned to immediate MDMA-assisted therapy than in those assigned to wait.

What limits the finding

The wait-list group did not receive a matching placebo and psychotherapy package during the initial comparison. Expectation, attention and psychotherapy can influence the observed difference.

Study identifiers · NCT05138068

Sources

Open this evidence page

MDMA · Anxiety associated with a life-threatening illnessEighteen patients with anxiety related to a life-threatening illness were randomized.
Treatment study

Study or clinical setting

Small randomized, blinded, placebo-controlled pilot

What was reported

Eighteen patients with anxiety related to a life-threatening illness were randomized. Mean trait-anxiety scores fell by 23.5 points in the MDMA group and 8.8 with placebo. The prespecified between-group comparison missed conventional statistical significance (p = 0.056).

What limits the finding

The estimate is imprecise. A larger trial would be necessary to establish whether the intervention improves this form of anxiety.

Study identifiers · NCT02427568

Sources

Open this evidence page

MDMA · Alcohol use disorderFourteen adults received MDMA-assisted psychotherapy after clinical detoxification.
Treatment study

Study or clinical setting

Open-label feasibility study after alcohol detoxification

What was reported

Fourteen adults received MDMA-assisted psychotherapy after clinical detoxification. Participants reported substantially lower average alcohol consumption nine months later than before detoxification.

What limits the finding

The comparison was with participants’ own pre-detox drinking. The contributions of detoxification, therapy, time and MDMA cannot be separated.

Study identifiers · NCT04158778

Sources

Open this evidence page

MDMA · Co-occurring PTSD and alcohol use disorderA 2026 pilot followed ten veterans with both diagnoses.
Treatment study

Study or clinical setting

Open-label veteran pilot and subsequent randomized protocols

What was reported

A 2026 pilot followed ten veterans with both diagnoses. PTSD severity fell and participants reported fewer heavy-drinking days. The authors judged the change in alcohol outcomes below their threshold for clinical significance. Separate controlled trials address both disorders.

What limits the finding

The pilot was too small and uncontrolled to establish an effect on drinking or to determine how much change came from psychotherapy. Larger trials have separate protocols and outcomes.

Study identifiers · NCT05943665 · NCT07118839 · NCT05709353

Sources

Open this evidence page

MDMA · Postpartum PTSD with opioid use disorderThe University of New Mexico plans to study postpartum participants with both PTSD and opioid use disorder.
Treatment study

Study or clinical setting

Registered open-label pilot

What was reported

The University of New Mexico plans to study postpartum participants with both PTSD and opioid use disorder. The primary outcome concerns PTSD symptoms.

What limits the finding

No study results were posted in the reviewed record. The design cannot establish an effect on opioid use disorder, broader perinatal safety or outcomes during pregnancy.

Study identifiers · NCT05219175

Sources

Open this evidence page

MDMA · Obsessive-compulsive disorderA Stanford study asks whether MDMA-assisted cognitive behavioral therapy improves obsessive-compulsive symptoms, measured using the Yale-Brown Obsessive Compulsive Scale.
Treatment study

Study or clinical setting

Randomized phase 2 psychotherapy augmentation study

What was reported

A Stanford study asks whether MDMA-assisted cognitive behavioral therapy improves obsessive-compulsive symptoms, measured using the Yale-Brown Obsessive Compulsive Scale. The active comparison uses methamphetamine with CBT.

What limits the finding

The target enrollment is 40. The reviewed registry record lists recruiting and has no posted results.

Study identifiers · NCT05783817

Sources

Open this evidence page

MDMA · Borderline personality disorderYale is examining short-term changes in self-reported social cognition in adults with borderline personality disorder after study-administered MDMA.
Mechanism study

Study or clinical setting

Early open-label social-cognition study

What was reported

Yale is examining short-term changes in self-reported social cognition in adults with borderline personality disorder after study-administered MDMA.

What limits the finding

The registry targets ten adults and has no posted results. The primary endpoint does not establish a durable effect on symptoms, relationships or functioning.

Study identifiers · NCT06683014

Sources

Open this evidence page

MDMA · Pathological narcissismA University of Washington trial studies MDMA-assisted therapy in participants with pathological narcissism.
Treatment study

Study or clinical setting

Open-label single-group feasibility study

What was reported

A University of Washington trial studies MDMA-assisted therapy in participants with pathological narcissism. The main measures include participants’ ratings on the Pathological Narcissism Inventory.

What limits the finding

Twelve people were enrolled. The reviewed record has no posted results, and a single group cannot separate treatment effects from expectation or time.

Study identifiers · NCT06565494

Sources

Open this evidence page

MDMA · Adjustment disorder in people with cancer and their partnersThe study plans to enroll ten patient–partner pairs affected by cancer.
Treatment study

Study or clinical setting

Registered open-label dyadic pilot

What was reported

The study plans to enroll ten patient–partner pairs affected by cancer. It measures adjustment-disorder symptoms and relationship functioning after MDMA-assisted therapy.

What limits the finding

The registry has no posted results. Any eventual estimate requires attention to the small sample and the paired design.

Study identifiers · NCT05584826

Sources

Open this evidence page

MDMA · Eating-disorder symptoms in people with severe PTSDInvestigators examined changes in Eating Attitudes Test scores among people enrolled for severe PTSD.
Secondary outcome

Study or clinical setting

Exploratory analysis of a phase 3 PTSD trial

What was reported

Investigators examined changes in Eating Attitudes Test scores among people enrolled for severe PTSD. They reported exploratory differences favoring MDMA-assisted therapy on measures of eating-related symptoms.

What limits the finding

Selection was based on PTSD. Outcomes on a symptom questionnaire cannot establish efficacy for diagnosed anorexia nervosa, binge-eating disorder or bulimia nervosa.

Study identifiers · NCT03537014

Sources

Open this evidence page

MDMA · Anorexia nervosa and binge-eating disorderA proposed multi-site study would have examined MDMA-assisted psychotherapy for restricting-type anorexia nervosa and binge-eating disorder.
Withdrawn treatment study

Study or clinical setting

Registered trial withdrawn before enrollment

What was reported

A proposed multi-site study would have examined MDMA-assisted psychotherapy for restricting-type anorexia nervosa and binge-eating disorder.

What limits the finding

The registry lists zero participants enrolled. This protocol produced no patient outcomes.

Study identifiers · NCT04454684

Sources

Open this evidence page

MDMA · Bulimia nervosaA Mount Sinai study compares two versions of MDMA-assisted therapy with standard care in bulimia nervosa.
Treatment study

Study or clinical setting

Registered comparative pilot

What was reported

A Mount Sinai study compares two versions of MDMA-assisted therapy with standard care in bulimia nervosa. The main measure is the frequency of binge-eating episodes.

What limits the finding

The reviewed record lists recruiting, with a target of 40 and no posted results. The treatment’s effect on bingeing or compensatory behaviors remains unknown.

Study identifiers · NCT07542145

Sources

Open this evidence page

MDMA · Social functioning in autistic adults · R-MDMAFive autistic adults participated in a study of R-MDMA, one of the two mirror-image forms of MDMA.
Treatment study

Study or clinical setting

Open-label pilot of the R-enantiomer DT402

What was reported

Five autistic adults participated in a study of R-MDMA, one of the two mirror-image forms of MDMA. The sponsor described exploratory changes in rigidity and social engagement.

What limits the finding

The report is sponsor-disclosed and uncontrolled. The preparation differs from the mixed-enantiomer MDMA in the social anxiety trial. Its findings cannot establish a change in core autism features.

Study identifiers · NCT07303907

Sources

Open this evidence page

MDMA · PTSD with moral injuryA study in veterans with PTSD and moral injury assesses PTSD symptoms and explores changes in relationships, hyperarousal and neural responses.
Mechanism and treatment study

Study or clinical setting

Registered trial in veterans

What was reported

A study in veterans with PTSD and moral injury assesses PTSD symptoms and explores changes in relationships, hyperarousal and neural responses.

What limits the finding

No outcomes were posted in the reviewed record. Moral injury here describes a study population and mechanism under investigation.

Study identifiers · NCT06394284

Sources

Open this evidence page

MDMA · Occupational distress in healthcare providers and first respondersOne protocol includes healthcare workers and first responders with adjustment disorder or PTSD.
Exploratory research

Study or clinical setting

Registered studies of stress symptoms and well-being

What was reported

One protocol includes healthcare workers and first responders with adjustment disorder or PTSD. Another focuses on well-being among mental healthcare providers.

What limits the finding

The populations and outcomes differ. These records have no posted efficacy results and cannot establish effectiveness for occupational burnout.

Study identifiers · NCT05455996 · NCT07102576

Sources

Open this evidence page

MDMA · Dissociation, depression and sleep symptoms in PTSDA 2026 review combined seven randomized trials of MDMA-assisted psychotherapy for PTSD.
Secondary outcome

Study or clinical setting

Systematic review of randomized PTSD trials

What was reported

A 2026 review combined seven randomized trials of MDMA-assisted psychotherapy for PTSD. The pooled data suggested improvements in dissociative symptoms, depressive symptoms and functional disability. The analysis found no clear improvement in sleep quality relative to controls.

What limits the finding

These outcomes came from PTSD populations and cannot establish benefit for a primary dissociative or sleep disorder. The studies shared a sponsor, and participants could often identify their assignment.

Sources

Open this evidence page

MDMA · Chronic pain in people with PTSDAmong 32 participants who completed pain assessments during a PTSD study, people starting with moderate or high pain reported less intense pain after therapy.
Secondary outcome

Study or clinical setting

Exploratory analysis of open-label PTSD data

What was reported

Among 32 participants who completed pain assessments during a PTSD study, people starting with moderate or high pain reported less intense pain after therapy. Nine participants in the highest-pain subgroup also reported less pain-related disability.

What limits the finding

The subgroups were small and there was no control arm. The analysis cannot establish analgesic efficacy. Separate protocols investigate fibromyalgia and chronic neuropathic pain.

Study identifiers · NCT03282123 · NCT06066853 · NCT07301632

Sources

Open this evidence page